Glycerin

Glycerin

SCHEMBL203757

CC(=O)O.CC(=O)O.OCC(O)CO

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Glycerin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.60
ALDH1A1 P00352 1/20 0.60
FFAR3 O14843 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47
OR51E2 Q9H255 1/20 0.45
SLC22A6 Q4U2R8 1/20 0.40
THRB P10828 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
AKR1B1 P15121 1/20 0.38
TP53 P04637 1/20 0.37
PDE4A P27815 1/20 0.36
SLC22A16 Q86VW1 1/20 0.35
MAPT P10636 1/20 0.35
TGFBR1 P36897 1/20 0.34
ACACB O00763 1/20 0.34
ACACA Q13085 1/20 0.34
KDM4E B2RXH2 1/20 0.34
DUSP3 P51452 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycerin SCHEMBL29623841 1.00 LMNA (0.60) LMNAALDH1A1FFAR3LCKFYN
Glycerin SCHEMBL15061 1.00 LMNA (0.60) LMNAALDH1A1FFAR3LCKFYN
Glycerin SCHEMBL30460570 1.00 LMNA (0.60) LMNAALDH1A1FFAR3LCKFYN
Glycerin SCHEMBL33458 1.00 LMNA (0.60) LMNAALDH1A1FFAR3LCKFYN
Glycerin SCHEMBL1685690 1.00 LMNA (0.60) LMNAALDH1A1FFAR3LCKFYN
Glycerin SCHEMBL1685695 1.00 LMNA (0.60) LMNAALDH1A1FFAR3LCKFYN
Glycerin SCHEMBL1685689 1.00 LMNA (0.60) LMNAALDH1A1FFAR3LCKFYN
Glycerin SCHEMBL31032269 1.00 LMNA (0.60) LMNAALDH1A1FFAR3LCKFYN
Glycerin SCHEMBL8151443 1.00 LMNA (0.60) LMNAALDH1A1FFAR3LCKFYN
Glycerin SCHEMBL29793596 1.00 LMNA (0.60) LMNAALDH1A1FFAR3LCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3355853-B1 ARTIFICIAL SWEAT COMPOSITION SYMRISE AG (DE) 2026-05-06 EP claimed
EP-3756489-B1 ELECTRONIC CIGARETTE FILLER AND ELECTRONIC CIGARETTE CARTRIDGE USING SAME FUTURE TECHNOLOGY CO LTD (JP) 2024-07-31 EP claimed
CN-116706179-A Preparation method and application of electrolyte of all-vanadium redox flow battery 江西江钒科技实业有限公司 2023-09-05 CN claimed
US-11446231-B2 Oral care compositions and methods for the same COLGATE-PALMOLIVE COMPANY (US) 2022-09-20 US claimed
US-20220184165-A1 Novel Compounds and Pharmaceutical Preparations DICOT AB (SE) 2022-06-16 US claimed
US-11261366-B2 Barrier pills containing viscoelastic surfactant and methods for using the same HALLIBURTON ENERGY SERVICES, INC. (US) 2022-03-01 US claimed
US-10828242-B2 Artificial sweat composition SYMRISE AG (DE) 2020-11-10 US claimed
US-20190105250-A1 ARTIFICIAL SWEAT COMPOSITION SYMRISE AG (DE) 2019-04-11 US claimed
US-9879503-B2 Methods of treating long-interval and high-contrast permeability subterranean formations with diverting fluids HALLIBURTON ENERGY SERVICES, INC. (US) 2018-01-30 US claimed
CN-106317436-A Ultraviolet prevention and heat insulation glass 张云德 2017-01-11 CN claimed
EP-1125497-B1 Product for virucidal disinfection of the hands KESLA FORSCHUNG U SERVICE KG (DE) 2003-06-18 EP claimed
EP-1244365-B1 METHOD FOR PRODUCING AN ACIDIFIED FILTER FOR TOBACCO PRODUCTS AND THE USE THEREOF REEMTSMA H F & PH (DE) 2003-05-02 EP claimed
CN-1384734-A Surface-modified microparticle compositions of biologically active substances RTP PHARMA INC (US) 2002-12-11 CN claimed
US-6391947-B1 MIXTURE CONTAINING WATER, COLORING AND WATER SOLUBLE POLYMER CANON KABUSHIKI KAISHA (JP) 2002-05-21 US claimed
EP-0738244-B1 PROCESS FOR PRODUCING CERAMIC GREEN COMPACTS BY DOUBLE LAYER COMPRESSION CERAMTEC AG (DE) 2000-11-08 EP claimed
CN-1240346-A Injectable depot gel composition and method of preparing the composition ALZA CORP (US) 2000-01-05 CN claimed
US-5667548-A Process for producing ceramic green compacts by double layer compression Graule, Thomas (CH) 1997-09-16 US claimed
EP-0383018-B1 Process for impregnating tobacco smoke filter fibres with polycarboxylic acid or salts thereof BAT CIGARETTENFAB GMBH (DE) 1994-01-05 EP claimed
EP-0346648-B1 PROCESS FOR IMPREGNATING THE FIBRES OF A TOBACCO SMOKE FILTER WITH DI- OR POLYCARBOXYLIC ACIDS OR THEIR ANHYDRIDES British-American Tobacco (Germany) GmbH (DE) 1993-01-07 EP claimed
US-3981798-A LIQUID EXTRACTION USING CERTAIN ETHERS AND ESTERSMONO-ETHYL OR MONO-METHYL ETHER OF GLYCERINE, GLYCERINE MONO- OR DI-ACETATE NALCO CHEMICAL COMPANY (US) 1976-09-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220184165-A1 Novel Compounds and Pharmaceutical Preparations PDE8B, PDE3B, PDE4D LMNA 4654/4885ALDH1A1 2608/4885FFAR3 4299/4885
US-11446231-B2 Oral care compositions and methods for the same RPN1, PSMC2, KRTCAP2 LMNA 1281/4885ALDH1A1 2545/4885FFAR3 1123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.